Press Releases May 1, 2026 04:30 PM

Ultralife Corporation to Report First Quarter Results on May 8, 2026

Ultralife Corporation announces Q1 2026 earnings release and investor webcast scheduled for May 8, 2026.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
ULBI

Ultralife Corporation will release its first quarter 2026 financial results on May 8, 2026, prior to market open. The company will hold an investor conference call and webcast to discuss results. Ultralife is a NASDAQ-listed company specializing in batteries, power solutions, and communication systems serving government, defense, and commercial sectors worldwide.

Ultralife Corporation to Report First Quarter Results on May 8, 2026
ULBI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ultralife to report Q1 2026 earnings before market open on May 8, 2026.
  • Investor conference call and webcast scheduled for investors to engage with management.
  • Company operates in battery and energy products as well as communication systems, serving government, defense, and commercial customers globally.

NEWARK, N.Y., May 01, 2026 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its first quarter results for the period ended March 31, 2026 before the market opens on Friday, May 8, 2026.

Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on May 8, 2026. Please see the call-in procedures which follow below.

NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE:

To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register-conf.media-server.com/register/BIa05f373879a942b691466d052a5da3ae. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again.

A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company’s website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include: Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit http://www.ultralifecorporation.com.

Company Contact:
Ultralife Corporation
Philip A. Fain
(315) 210-6110
pfain@ulbi.com
Investor Relations Contact:
Alliance Advisors IR
Jody Burfening
(212) 838-3777
jburfening@allianceadvisors.com

Risks

  • Uncertainty in quarter performance as actual financial results are not yet disclosed, which may affect investor sentiment.
  • Potential impact of global economic or geopolitical conditions on Defense and commercial sectors served.
  • Reliance on innovative engineering and problem solving requires continued R&D investment amid competitive environment.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026